200 Technology Square
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1133 articles about Moderna, Inc.
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second virtual ESG investor event at 8:00 a.m. ET on Thursday, December 7, 2023.
Research associates are always in demand. Check out these top companies currently hiring RAs.
Moderna, Inc., announced its participation in the following upcoming investor conferences.
Moderna, Inc. (NASDAQ:MRNA) today will unveil its comprehensive AI and digital strategy at its second Digital Investor Event. Building off its Manufacturing and Digital Day hosted in March 2020, the Company will showcase how AI continues to transform the organization and enhance its value creation.
BioSpace spoke with representatives of the two top-place finishers in our Best Places to Work list about their approaches to fostering an engaging workplace.
Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2024 Best Places to Work report for the third consecutive year.
Moderna, Inc. reported financial results and provided business updates for the third quarter of 2023.
While Moderna’s total revenue for the third quarter beat analyst expectations, the company Thursday reported a loss as demand for its COVID vaccines declined.
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna.
The Coalition for Epidemic Preparedness Innovations and Moderna, Inc. have entered into a strategic partnership that will harness Moderna's mRNA platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health.
Moderna, Inc. announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year.
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
Moderna, Inc. announced that the first participant has been dosed in a Phase 3 study of the Company's combination vaccine candidate against influenza and COVID-19 in the U.S. The trial is expected to enroll approximately 8,000 adults in the Northern Hemisphere.
Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a virtual Digital and AI Investor Event at 8:00 a.m. ET on Wednesday, November 8, 2023.
Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Moderna, Inc. (NASDAQ:MRNA) today announced positive interim results from the Phase 1/2 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19.
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
Moderna, Inc. has become aware that TRC Capital Investment Corporation has amended its unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price that is now $99.00 per share, down from $107.56 per share under the original offer.
In honor of World Cancer Research Day, BioSpace takes a deep dive into 10 therapeutic candidates with the potential to change the treatment landscape in lung, breast, colorectal cancer and more.
In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for Spikevax, its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.
During Wednesday’s annual R&D Day, Moderna said it is culling four programs from its pipeline, including two molecules that had been discontinued last year by AstraZeneca.